| [1] |
Tangjitgamol S, Khunnarong J, Srijaipracharoen S. Medical morbidities in endometrial cancer patients[J]. Int J Gynecol Cancer, 2014, 24(9):1623-1627.
|
| [2] |
Berretta R, Patrelli TS, Migliavacca C, et al. Assessment of tumor size as a useful marker for the surgical staging of endometrial cancer[J]. Oncol Rep, 2014, 31(5):2407-2412.
|
| [3] |
Baser E, Gungor T, Togrul C, et al. Preoperative prediction of poor prognostic parameters and adjuvant treatment in women with pure endometrioid type endometrial cancer：what is the significance of tumor markers？[J]. Eur J Gynaecol Oncol, 2014, 35(5):513-518.
|
| [4] |
Jiang T, Huang L, Zhang S. Preoperative serum CA125: a useful marker for surgical management of endometrial cancer[J]. BMC Cancer, 2015, 15:396.
|
| [5] |
Su F, Lang J, Kumar A, et al. Validation of candidate serum ovarian cancer biomarkers for early detection[J]. Biomark Insights, 2007, 2:369-375.
|
| [6] |
Farias-Eisner G, Su F, Robbins T, et al. Validation of serum biomarkers for detection of early- and late-stage endometrial cancer[J]. Am J Obstet Gynecol, 2010, 202(1):73.e1-e5.
|
| [7] |
Høgdall EV, Ringsholt M, Høgdall CK, et al. YKL-40 tissue expression and plasma levels in patients with ovarian cancer[J]. BMC Cancer, 2009, 9:8.
|
| [8] |
Fan JT, Li MJ, Shen P, et al. Serum and tissue level of YKL-40 in endometrial cancer[J]. Eur J Gynaecol Oncol, 2014, 35(3):304-308.
|
| [9] |
Kobayashi H, Terao T, Kawashima Y. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer[J]. J Clin Oncol, 1991, 9(6):983-987.
|
| [10] |
An YH, Zhang HF, Sun M, et al. sTn is a novel biomarker for typeⅠendometrial carcinoma[J]. Prog Biochem Biophys, 2012, 39(6):548-555.
|
| [11] |
Zhou C, Tong Y, Wawrowsky K, et al. PTTG acts as a STAT3 target gene for colorectal cancer cell growth and motility[J]. Oncogene, 2014, 33(7):851-861.
|
| [12] |
Feng ZZ, Chen JW, Yang ZR, et al. Expression of PTTG1 and PTEN in endometrial carcinoma：correlation with tumorigenesis and progression[J]. Med Oncol, 2012, 29(1):304-310.
|
| [13] |
Visvader JE, Lindeman GJ. Cancer stem cells in solid tumors：accumulating evidence and unresolved questions[J]. Nat Rev Cancer, 2008, 8(10):755-768.
|
| [14] |
Kyo S, Maida Y, Inoue M. Stem cells in endometrium and endometrial cancer: accumulating evidence and unresolved questions[J]. Cancer Lett, 2011, 308(2):123-133.
|
| [15] |
Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling[J]. Cancer Res, 2009, 69(14):5627-5629.
|
| [16] |
Choijaints B , Jimi S, Kondo T, et al. CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor)[J]. Stem Cells, 2011, 29(10):1485-1495.
|
| [17] |
Li B, Zhang ZQ, Sheng LL, et al. Expression and clinicopathologic significance of the cancer stem cell markers CD133 and EpCAM in endometrial cancer[J]. Chin J Clin Oncol, 2012, 39(17):1281-1284.
|
| [18] |
Zhao L, Cui QC. Annexin A2 and pathogenesis cancer：an update[J]. Chin J Pathol, 2007, 36(2):129-132.
|
| [19] |
Zhang X, Liu S, Guo C, et al. The association of annexin A2 and cancers[J]. Clin Transl Oncol, 2012, 14(9):634-640.
|
| [20] |
Alonso-Alconada L, Santacana M, Garcia-Sanz P, et al. Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer[J]. Int J Cancer, 2015, 136(8):1863-1873.
|
| [21] |
Krainer AR, Mayeda A, Kozak D, et al. Functional expression of cloned human splicing factor SF2: homology to RNA-binding proteins, U1 70K, and Drosophila splicing regulators[J]. Cell, 1991, 66(2):383-394.
|
| [22] |
Gupta S, Batchu RB, Datta K. Purification, partial characterization of rat kidney hyaluronic acid binding protein and its localization on the cell surface [J]. Eur J Cell Biol, 1991, 56(1):58-67.
|
| [23] |
Majumdar M, Datta K. Assignment of cDNA encoding hyaluronic acid-binding protein 1 to human chromosome 17p12-p13[J]. Genomics, 1998, 51(3):476-477.
|
| [24] |
Zhang X, Zhang F, Guo L, et al. Interactome analysis reveals that C1QBP (complement component 1, q subcomponent binding protein) is associated with cancer cell chemotaxis and metastasis[J]. Mol Cell Proteomics, 2013, 12(11):3199-3209.
|
| [25] |
Chen YB, Jiang CT, Zhang GQ, et al. Increased expression of hyaluronic acid binding protein 1 is correlated with poor prognosis in patients with breast cancer[J]. J Surg Oncol, 2009, 100(5):382-386.
|
| [26] |
Rubinstein DB, Stortchevoi A, Boosalis M, et al. Receptor for the globular heads of C1q (gC1q-R, p33, hyaluronan-binding protein) is preferentially expressed by adenocarcinoma cells[J]. Int J Cancer, 2004, 110(5):741-750.
|
| [27] |
Parle-McDermott A, McWilliam P, Tighe O, et al. Serial analysis of gene expression identifies putative metastasis-associated transcripts in colon tumour cell lines[J]. Br J Cancer, 2000, 83(6):725-728.
|
| [28] |
Ghosh I, Chowdhury AR, Rajeswari MR, et al. Differential expression of hyaluronic acid binding protein 1(HABP1)/P32/C1QBP during progression of epidermal carcinoma[J]. Mol Cell Biochem, 2004, 267(1-2):133-139.
|
| [29] |
Fogal V, Zhang L, Krajewski S, et al. Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma[J]. Cancer Res, 2008, 68(17):7210-7218.
|
| [30] |
Zhao J, Liu T, Yu G, et al.Overexpression of HABP1 correlated with clinicopathological characteristics and unfavorable prognosis in endometrial cancer[J]. Tumour Biol, 2015, 36(2):1299-1306.
|
| [31] |
Harashima H, Dissmeyer N, Schnittger A. Cell cycle control across the eukaryotic kingdom[J]. Trends Cell Biol, 2013, 23(7):345-356.
|
| [32] |
Malumbres M, Barbacid M. Cell cycle, CDKs and cancer：a changing paradigm[J]. Nat Rev Cancer, 2009, 9(3):153-166.
|
| [33] |
Cooper WA, Kohonen-Corish MR, McCaughan B, et al. Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer [J]. Histopathology, 2009, 55(1):28-36.
|
| [34] |
Nozoe T, Korenaga D, Kabashima A, et al. Significance of cyclin B1 expression as an independent prognostic indicator of patients with squamous cell carcinoma of the esophagus[J]. Clin Cancer Res, 2002, 8(3):817-822.
|
| [35] |
Niméus-Malmström E, Koliadi A, Ahlin C, et al.Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort[J]. Int J Cancer, 2010, 127(4):961-967.
|
| [36] |
Begnami MD, Fregnani JH, Nonogaki S, et al. Evaluation of cell cycle protein expression in gastric cancer：cyclin B1 expression and its prognostic implication[J]. Hum Pathol, 2010, 41(8):1120-1127.
|
| [37] |
Shin JU, Lee CH, Lee KT, et al. Prognostic significance of ATM and cyclin B1 in pancreatic neuroendocrine tumor[J]. Tumor Biol, 2012, 33(5):1645-1651.
|
| [38] |
Santala S, Talvensaari-Mattila A, Soini Y, et al. Prognostic value of cyclin B in endometrial endometrioid adenocarcinoma[J]. Tumor Biol, 2015, 36(2): 953-957.
|
| [39] |
Edqvist PH, Huvila J, Forsström B, et al. Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma[J]. Gynecol Oncol, 2015, 137(3):529-537.
|
| [40] |
Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas[J]. Cancer Res, 2005, 65(6):2162-2169.
|
| [41] |
Plotti F, Capriglione S, Terranova C, et al. Does HE4 have a role as biomarker in the recurrence of ovarian cancer？[J]. Tumour Biol, 2012, 33(6):2117-2123.
|
| [42] |
Capriglione S, Plotti F, Miranda A, et al. Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study[J]. Tumor Biol, 2015, 36(6):4151-4156.
|
| [43] |
Shang P, Meng F, Liu Y, et al. Overexpression of ANCCA/ATAD2 in endometrial carcinoma and its correlation with tumor progression and poor prognosis[J]. Tumor Biol, 2015, 36(6):4479-4485.
|
| [44] |
Wang Q, Li Y, Zhou J, et al. Clinical significance of Sam68 expression in endometrial carcinoma[J]. Tumor Biol, 2015, 36(6):4509-4518.
|
| [45] |
Lee DW, Chong GO, Lee YH, et al. Role of SUVmax and GLUT-1 expression in determining tumor aggressiveness in patients with clinical stage Ⅰ endometrioid endometrial cancer[J]. Int J Gynecol Cancer, 2015, 25(5):843-849.
|
| [46] |
Ikeda Y, Oda K, Ishihara H, et al. Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy[J]. Br J Cancer, 2015, 113(10):1477-1483.
|
| [47] |
Stewart CJ, Crook ML. Fascin expression in undifferentiated and dedifferentiated endometrial carcinoma[J]. Hum Pathol, 2015, 46(10):1514-1520.
|